These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 39308

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [MIF (melanocyte-stimulating hormone release-inhibiting factor) and Parkinson's disease].
    Carolei A, Meco G, Casacchia M, Agnoli A.
    Acta Neurol (Napoli); 1976; 31(4):475-8. PubMed ID: 16441
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A, Baldassarre M, Ruggieri S, Falaschi P, Urso RD, Rocco A.
    J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
    [Abstract] [Full Text] [Related]

  • 5. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J, Avila C, Bazán E, García E, Gervás J, Maseda C, Mena M, Muradas V, Ramos JA.
    Med Clin (Barc); 1982 Apr 01; 78(7):259-64. PubMed ID: 7087591
    [No Abstract] [Full Text] [Related]

  • 6. [The influence of MIF (melanocyte-stimulating hormone-release inhibiting factor) on psychomotor function and mood in parkinsonian patients. Preliminary report (author's transl)].
    Schneider E, Fischer PA, Jacobi P, Reh W.
    Arzneimittelforschung; 1978 Apr 01; 28(8):1296-7. PubMed ID: 37848
    [Abstract] [Full Text] [Related]

  • 7. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
    Pan JB.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug 01; 18(4):205-8. PubMed ID: 2866940
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
    Xu DL, Yu WC, Pan GB, Chen SD.
    Adv Neurol; 1987 Aug 01; 45():587-90. PubMed ID: 2881450
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Potentiation of levodopa effect by intravenous L-prolyl-L-leucyl-glycine amide in man.
    Barbeau A.
    Lancet; 1975 Oct 11; 2(7937):683-4. PubMed ID: 52054
    [Abstract] [Full Text] [Related]

  • 12. Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
    Galea-Debono A, Jenner P, Marsden CD, Parkes JD, Tarsy D, Walters J.
    J Neurol Neurosurg Psychiatry; 1977 Feb 11; 40(2):162-7. PubMed ID: 864480
    [Abstract] [Full Text] [Related]

  • 13. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP, Scotti de Carolis A, Longo VG.
    Pharmacol Biochem Behav; 1975 Feb 11; 3(2):235-42. PubMed ID: 238221
    [Abstract] [Full Text] [Related]

  • 14. MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders.
    Sandyk R.
    Int J Neurosci; 1990 May 11; 52(1-2):59-65. PubMed ID: 1979968
    [Abstract] [Full Text] [Related]

  • 15. Dissociation of growth hormone and prolactin secretion in Parkinson's disease following chronic L-dopa therapy.
    Malarkey WB, Cyrus J, Paulson GW.
    J Clin Endocrinol Metab; 1974 Aug 11; 39(2):229-35. PubMed ID: 4371345
    [No Abstract] [Full Text] [Related]

  • 16. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE.
    J Neurol Neurosurg Psychiatry; 1981 Dec 11; 44(12):1116-23. PubMed ID: 7334406
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A, Giovannini P, Novelli A, Cocchi D, Caraceni T, Müller EE.
    Acta Endocrinol (Copenh); 1982 Mar 11; 99(3):344-51. PubMed ID: 6803485
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.